PROMEDIUS
Story
We are on a mission
to redefine the way we age.
Mission
Healthy Aging through AI
At PROMEDIUS, we redefine aging not as an inevitable decline but as a new possibility for healthy aging.
We hold a firm belief that with our advanced AI technology, we can enable healthy aging and help humanity embrace a brighter future.
Leadership
Co-founders
Advisors
Journey
2025
Received clearance from the Ministry of Korea Food and Drug Safety (MFDS) for PROS® CXR: OSTEO.
2024
Raised Series A2 investment.
Achieved the world’s highest AUC of 0.94.
Presented 15 abstracts at major conferences, including RSNA, KSBMR, ASBMR.
Designated as an innovative medical device by the MFDS.
Signed MOU with the Korean Society of Sarcopenia.
Sponsored the International Osteoporosis Foundation (IOF).
Joined *PRECCO, a 5-year collaboration between WHO, IOF, and ESCEO for industry-academia cooperation.
(*PRECCO = Precompetitive Consortium on Osteoporosis and Bone Health)
2023
Pivoted to AI software for chest X-ray-based osteoporosis diagnosis PROS® CXR: OSTEO.
Started research collaboration with Massachusetts General Hospital, Penn. State Health, Seoul National University Hospital, etc.
2022
Obtained 24 domestic and international patents.
Winner of the Startup Pitching Grand Prize at The 20th World Korean Business Convention.
2021
Raised Series A1 investment.
Received the Small Business Minister’s Award.
2020
Selected for the TIPS R&D program by the Ministry of SMEs and Startups.
2019
PROMEDIUS Corporation established.